A Study of ETX-19477 in Patients With Advanced Solid Malignancies
Phase 1/2
120
about 2.6 years
18+
14 sites in AZ, CT, FL +10
What this study is about
Researchers are testing a new drug called ETX-19477 to see if it's safe and effective for people with advanced solid cancers. The trial will involve adults, and the expected duration is 962 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take ETX-19477
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: To characterize the safety and tolerability of ETX-19477, the maximum tolerated dose (MTD) and/or RP2D of ETX-19477
Secondary: To assess the preliminary anti-tumor activity of ETX-19477 in participants by measuring disease control rate (DCR) using RECIST v1.1, To assess the preliminary anti-tumor activity of ETX-19477 in participants by measuring duration of response (DOR) using RECIST v1.1, To assess the preliminary anti-tumor activity of ETX-19477 in participants by measuring objective response rate (ORR) using RECIST v1.1, To characterize the pharmacokinetic (PK) profile of ETX-19477 by measuring elimination half-life (t1/2), To characterize the pharmacokinetic (PK) profile of ETX-19477 by measuring maximum blood concentration (tmax), To characterize the pharmacokinetic (PK) profile of ETX-19477 by measuring maximum plasma concentration (Cmax), To further characterize the pharmacokinetic (PK) profile of ETX-19477 by the Area Under the Blood Concentration-Time Curve (AUC0-t, AUC0-inf), Clearance (CL), Volume of Distribution (Vd)
Oncology